Pinealon vs SS-31
Both Pinealon and SS-31 are used for longevity. Here's how their evidence, dosing, and regulatory status actually compare.
Pinealon
Evidence CPinealon (EDR)
A short tripeptide developed in Russia for cognitive aging and oxidative stress. Limited Western clinical evidence.
View full Pinealon profile →SS-31
Evidence B+Elamipretide (SS-31)
A cell-permeable tetrapeptide that targets cardiolipin in the inner mitochondrial membrane. Investigated for primary mitochondrial myopathy, heart failure, and dry age-related macular degeneration.
View full SS-31 profile →Side-by-Side
| Attribute | Pinealon | SS-31 |
|---|---|---|
| Evidence Grade | C | B+ |
| FDA Status | Not FDA-approved — Russian-origin research peptide | Not FDA-approved — Phase 3 trials for primary mitochondrial myopathy |
| Typical Dose | 5–10 mg daily for 10–20 days (subcutaneous, cycled) | Trial range: 40 mg subcutaneous daily |
| Clinics Indexed | 9 | 29 |
| Categories | cognitive, longevity | mitochondrial, longevity |
Key reported benefits — Pinealon
- ✓Cognitive function (preclinical)
- ✓Reduced oxidative damage
- ✓Sleep/circadian effects
Key reported benefits — SS-31
- ✓Mitochondrial cardiolipin support
- ✓ATP production
- ✓Reduced oxidative damage
Educational use only
This comparison is for educational purposes and not medical advice. Peptide selection should be made with a licensed medical professional based on your individual goals, health history, and current evidence quality.